RDTCF (Rapid Dose Therapeutics) LT-Debt-to-Total-Asset: 0.61 (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RDTCF Rapid Dose Therapeutics Corp RDTCF
29 GF Score
Price $0.07
GF Value $0.22
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Rapid Dose Therapeutics LT-Debt-to-Total-Asset?

Rapid Dose Therapeutics RDTCF -7.61% 29 LT-Debt-to-Total-Asset is 0.61 as of Feb. 2026. GuruFocus rates RDTCF with a GF Score™ of 29/100 and a GF Value™ of $0.22 (Possible Value Trap). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Rapid Dose Therapeutics's long-term debt to total assests ratio for the quarter that ended in Feb. 2026 was 0.61.

Rapid Dose Therapeutics's long-term debt to total assets ratio increased from Feb. 2025 (0.00) to Feb. 2026 (0.61). It may suggest that Rapid Dose Therapeutics is progressively becoming more dependent on debt to grow their business.

Rapid Dose Therapeutics  (OTCPK:RDTCF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Rapid Dose Therapeutics LT-Debt-to-Total-Asset Related Terms

Rapid Dose Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Rapid Dose Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics LT-Debt-to-Total-Asset Chart

Rapid Dose Therapeutics Annual Data
Trend Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.01 1.13 0.00 0.61

Rapid Dose Therapeutics Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.58 0.53 0.58 0.61
RDTCF
29GF Score
Rapid Dose Therapeutics Corp RDTCF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapid Dose Therapeutics LT-Debt-to-Total-Asset Calculation

Rapid Dose Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Feb. 2026 is calculated as

LT Debt to Total Assets (A: Feb. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Feb. 2026 )/Total Assets (A: Feb. 2026 )
=1.475/2.405
=0.61

Rapid Dose Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2026 is calculated as

LT Debt to Total Assets (Q: Feb. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Feb. 2026 )/Total Assets (Q: Feb. 2026 )
=1.475/2.405
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.61 mean?
Rapid Dose Therapeutics (RDTCF) has a LT-Debt-to-Total-Asset of 0.61 as of Feb. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Rapid Dose Therapeutics and its competitors.
Is Rapid Dose Therapeutics' LT-Debt-to-Total-Asset too high?
Rapid Dose Therapeutics' current LT-Debt-to-Total-Asset is 0.61. Overall, Rapid Dose Therapeutics has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Rapid Dose Therapeutics' LT-Debt-to-Total-Asset of 0.61 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Rapid Dose Therapeutics and its competitors. Rapid Dose Therapeutics's current LT-Debt-to-Total-Asset is 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.22, compared to a current price of $0.07 — trading 67% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.61. Rapid Dose Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current LT-Debt-to-Total-Asset is 0.61 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?

Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued. The current stock price of $0.07 is trading 67% below its estimated GF Value™ of $0.22. GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.

Key valuation signals for RDTCF:

  • LT-Debt-to-Total-Asset: 0.61
  • GF Value™: $0.22 vs. price of $0.07 (67% below fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rapid Dose Therapeutics Business Description

Other Exchanges DOSE:Canada
Address 1121 Walkers Line, Unit 3a, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
29GF Score

Get the complete analysis for RDTCF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price
$0.22
GF Value